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p21-activated kinases are important signaling kinases for which no specific chemical inhibitors are known. In
this issue of Chemistry & Biology, Deacon et al. target allosteric transitions undergone during PAK activation
to identify a selective inhibitor (Deacon et al., 2008).The p21-activated kinases (PAKs) are
important mediators of Rho GTPase sig-
naling, and are implicated in biological
processes ranging from cytoskeletal
dynamics and motility to tumorigenesis
and apoptosis (Bokoch, 2003; Arias-
Romero and Chernoff, 2008). The Group
I PAKs (PAKs1–3) are regulated by an
autoinhibitory mechanism that is relieved
by the binding of active Rac and Cdc42
GTPases to an N-terminal recognition
domain. The binding of other regulatory
proteins, sphingolipids, and the kinase-
mediated phosphorylation of specific
sites within the PAK N terminus can re-
lease PAK autoinhibition as well.
Most of the biological activities of
Group I PAKs have been determined us-
ing the autoinhibitory domain contained
within aa 83–149 of PAK1 expressed in
trans as a means to inhibit the Group I
PAKs. While extremely useful, there are
potential problems inherent in this
approach. These include the need to in-
troduce the autoinhibitory peptide frag-
ment into cells, and the potential for this
region to bind unintended targets, includ-
ing Rac or Cdc42, and possibly other pro-
teins (Thullberg et al., 2007). Likewise,
PAKs have scaffolding functions that af-
fect cell signaling, apart from their action
as kinases. Thus, depletion of PAK pro-
teins using siRNA not only affects sub-
strate phosphorylation, but also localiza-
tion of proteins to the PAK scaffold.
In general, the highly conserved ATP
binding pockets of kinases have been
amenable to the identification of small
molecular weight inhibitors that compete
for ATP binding. The PAKs have been
a major exception because screening
efforts for such competitive inhibitors
have, to this author’s knowledge, not
been successful. In this issue of Chemis-
try & Biology, Peterson and colleagues
use a screening approach based on theidentification of allosteric inhibitors of the
conformational changes that PAK un-
dergoes during activation to identify PAK
inhibitors (Deacon et al., 2008).
Many current inhibitor screens make
use of constitutively activated forms of
the kinase and target enzyme active sites.
In nature, however, protein function is
often regulated through allostery, a phe-
nomenon whereby the binding of a small
molecule to one site regulates the activity
of another, remote, site on the protein.
Allosteric regulators act by altering a con-
formational equilibrium of the protein
between active and inactive states. Such
equilibria can also be targeted by nonnat-
ural small molecules that perturb these
conformational transitions. The approach
of targeting allosteric transition states
during protein activation has been suc-
cessfully used to identify inhibitors of other
enzymes, e.g., Wiskostatin, an N-WASP
inhibitor that stabilizes the autoinhibited
conformation of this cytoskeletal-regula-
tory enzyme (Peterson et al., 2004). In
addition to providing alternative avenues
for inhibiting enzymes, this approach, in
principle, could allow targeting of alloste-
rically regulated proteins that lack cata-
lytic sites. Indeed, many clinically impor-
tant signaling pathways are mediated
by proteins lacking catalytic activity that
serve instead as scaffolding, structural,
or regulatory components. Endogenous
protein inhibitors (e.g., the tumor suppres-
sor Merlin) or activators (e.g., CIB1) of
PAK1 kinase activity that target the PAK1
autoregulatory strategy have been de-
scribed, suggesting that modulation of the
autoregulatory domain may be a normal
physiological strategy for modulating
PAK catalytic activity.
The primary screen of a 33,000 small
molecular weight compound library per-
formed by Deacon et al. was based on
the catalytic activity of full-length PAK1Chemistry & Biology 15, April 200activated by the allosteric modulator
Cdc42-GTPgS. This screen identified
342 compounds able to inhibit PAK activ-
ity by greater than 3 standard deviations
below the control mean. A secondary
screen was conducted in the presence of
1 mM ATP to minimize detection of ATP-
competitive inhibitors, reducing the final
number of active inhibitors to 32. 2,20–di-
hydroxy-1,10–dinaphthyldisulfide (termed
IPA-3 for allosteric inhbitor targeting
PAK1 activation-3), a highly active com-
pound with an IC50 of 2.5 mM, was chosen
for further characterization.
IPA-3 was shown not to act via com-
petition with PAK1 ATP binding, nor did
it (as a disulfide) target exposed cysteine
residues on PAK1. Inhibition was ob-
served when either Cdc42-GTPgS or
sphingosine was used as an enzyme
activator. Interestingly, order-of-addition
experiments demonstrated a dramatic
reduction in the efficacy of IPA-3 when
added after PAK1 preactivation and auto-
phosphorylation had occurred.
In the autoinhibited conformation, the
activation loop (aa 408–428) of PAK1 is
folded into the catalytic site, thereby
masking the activation loop and prevent-
ing access to the critical Thr423 residue
(Figure 1). Upon relief of autoinhibition,
a conformational change in the activation
loop exposes Thr423 to phosphorylation
by other PAK1 monomers, as well as
other kinases (Chong et al., 2001; Zenke
et al., 1999). Deacon et al. demonstrate
that IPA-3 does not stabilize the native
autoinhibited conformation of PAK1, as
originally suspected, but actually pro-
motes an inactive conformation of PAK1
in which Thr423 is exposed (see Figure 1).
Indeed, PAK1 could be phosphorylated at
Thr423 by added exogenous kinases, but
was not phosphorylated at that site by
PAK1 itself. Phosphorylation of Thr423
by exogenous kinase did not overcome8 ª2008 Elsevier Ltd All rights reserved 305
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The autoinhibition of Pak1 is mediated by formation of an inactive homodimer in which the autoregulatory
region (red) of one monomer binds and inhibits in trans the catalytic domain of its partner, and vice versa
(Lei et al., 2000). The kinase inhibitory segment of the autoregulatory region (indicated by triangular shape)
binds in the activation site cleft and sequesters the kinase activation loop in an inactive conformation. The
binding of active GTPase to a region partially overlapping the autoinhibitory region causes dissociation of
the PAK dimer and displacement of the inhibitory interaction through destabilization of the inhibitory do-
main (indicated by change in shape). This results in a transient inactive ‘‘closed’’ enzyme conformation.
This conformation quickly shifts to an ‘‘open’’ conformation in which the T423 site in the activation
loop is exposed, resulting in its rapid phosphorylation, either by PAK monomers acting ‘‘in trans’’ or by
exogenous kinases such as PDK1, and enzyme activation. IPA-3 induces (or stabilizes) a unique state
characterized by an open conformation in which T423 is exposed, yet PAK1 remains inactive. Auto-
phosphorylation events at multiple sites within PAK1 stabilize the catalytically competent, monomeric
conformation (Chong et al., 2001; Zenke et al., 1999).the inhibitory effect of IPA-3, however.
Whether IPA-3 induces this catalytically
inactive conformation of PAK1, or stabi-
lizes a previously unsuspected transition
intermediate distinct from the autoinhib-
ited conformation, is unknown. A precise
understanding of the inhibitory mecha-
nism will necessitate detailed structural
analyses.
While all three Group I PAKs were in-
hibited by IPA-3, the Group II PAKs, with
catalytic domains that are highly con-
served with those of the Group I PAKs
but which are not regulated by an auto-
regulatory strategy (Arias-Romero and
Chernoff, 2008), were insensitive to IPA-
3. Indeed, the high degree of specificity
of the IPA-3 inhibitor was particularly im-
pressive—only 9 of 214 kinases tested
(4% of total) were inhibited by more than
50% at 10 mM IPA-3. In comparison, the
highly selective Bcr-Abl inhibitor imatinib306 Chemistry & Biology 15, April 2008 ª20inhibited 12% of kinases tested in the
same assay. Efficacy and selectivity of
IPA-3 toward PAK1 was also observed
in intact cells. Specificity profiling of clini-
cal kinase inhibitors has revealed that
many ‘‘selective’’ compounds also target
seemingly unrelated kinases (Karaman
et al., 2008). IPA-2 achieves a degree of
selectivity comparable to that of the highly
specific clinical inhibitors imatinib and
gelfitinib. Thus, IPA-3 is a unique Group I
PAK inhibitor that achieves a high degree
of specificity by targeting the distinct
autoregulatory mechanism used by the
Group I PAKs.
The present study provides an excellent
demonstration of the potential utility of
screening for allosteric agents for the
identification of novel inhibitors of en-
zymes that have proven recalcitrant to
conventional screens based upon target-
ing of the catalytic site. The availability of08 Elsevier Ltd All rights reservedselective chemical inhibitors of PAKs will
hopefully help to resolve confounding
issues raised by the absence of cytoskel-
etal and other defects in PAK1 knockout
mice. It has been hypothesized that the
activity of other Group I PAKs may com-
pensate for the loss of PAK1. Likewise,
substantial data have implicated PAK1 in
processes such as cancer and metastasis
(Kumar et al., 2006), and in neuronal
mechanisms contributing to mental
retardation and neurodegenerative dis-
eases (Boda et al., 2006). Inhibitors of
Group I PAKs have been suggested as a
potential basis for clinical therapy in such
conditions. The identification of IPA-3
and related compounds provides a
long-awaited opportunity to test these
hypotheses.
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